Aromatase/CYP19A1 Inhibitor

Aromatase/CYP19A1 Inhibitors (33):

Cat. No.	Product Name	Effect	Purity

HY-14248

Letrozole	Inhibitor	99.95%
Letrozole (CGS 20267) is a potent, selective, reversible and orally active non-steroidal inhibitor of aromatase, with an IC₅₀ of 11.5 nM. Letrozole selective inhibits estrogen biosynthesis, and can be used for the research of breast cancer.

HY-14274

Anastrozole	Inhibitor	99.99%
Anastrozole is a potent, highly selective aromatase inhibitor, which inhibits human placental aromatase with an IC₅₀ of 15 nM.

HY-N0292

Oleuropein	Inhibitor	99.05%
Oleuropein, found in olive leaves and oil, exerts antioxidant, anti-inflammatory and anti-atherogenic effects through direct inhibition of PPARγ transcriptional activity. Oleuropein induces apoptosis in breast cancer cells via the p53-dependent pathway and through the regulation of Bax and Bcl2 genes. Oleuropein also inhibits aromatase.

HY-13632

Exemestane	Inhibitor	99.92%
Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC₅₀s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research.

HY-125833

Alpha-Naphthoflavone	Inhibitor	98.54%
Alpha-Naphthoflavone is an orally active flavonoid that is a potent, competitive inhibitor of aromatase< b>aromatase. < b > IC < sub > 50 < / sub > < / b > and < b > K < sub > I < / sub > < / b > value were 0.5 and 0.2 microns. Alpha-Naphthoflavone can inhibit cell proliferation and induce apoptosis.

HY-B0237

Aminoglutethimide	Inhibitor	98.79%
Aminoglutethimide is an aromatase inhibitor with IC50 of 10 μM.

HY-18719B

Endoxifen hydrochloride	Inhibitor	98.75%
Endoxifen hydrochloride is a key active metabolite of Tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen hydrochloride has the potential for breast cancer study.

HY-14247A

Fadrozole	Inhibitor	99.78%
Fadrozole (CGS 16949A free base) is a potent, selective and nonsteroidal inhibitor of aromatase with an IC₅₀ of 6.4 nM.

HY-18719E

Endoxifen	Inhibitor	99.42%
Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study.

HY-14247

Fadrozole hydrochloride	Inhibitor	99.34%
Fadrozole hydrochloride (CGS 16949A) is a potent, selective and nonsteroidal inhibitor of aromatase with an IC₅₀ of 6.4 nM.

HY-W392925

(R)-(+)-Aminoglutethimide	Inhibitor
(R)-(+)-Aminoglutethimide is a potent and orally active aromatase inhibitor. (R)-(+)-Aminoglutethimide has the potential for the research of breast cancer.

HY-N7128

Flavanone	Inhibitor	99.84%
Flavanone is a naturally occurring flavone. Flavanone has inhibitory activity for human estrogen synthetase (aromatase).

HY-150775

Nonsteroidal aromatase inhibitor 1	Inhibitor	98.88%
Nonsteroidal aromatase inhibitor 1 (Compound 13h) is a nonsteroidal aromatase (CYP19A1) inhibitor (IC₅₀=0.09 nM). Nonsteroidal aromatase inhibitor 1 has potential for breast cancer research. Nonsteroidal aromatase inhibitor 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-13632R

Exemestane (Standard)	Inhibitor	99.63%
Exemestane (Standard) is the analytical standard of Exemestane. This product is intended for research and analytical applications. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC₅₀s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research.

HY-N9551

Eriodictyol chalcone	Inhibitor
Eriodictyol chalcone possesses both anti-aromatase and an anti-17β-HSD activity.

HY-19599

Vorozole	Inhibitor
Vorozole is a potent and selective, orally active non-steroidal aromatase inhibitor. Vorozole shows antitumor activity in vivo. Vorozole has the potential for the research of mammary cancer.

HY-14247B

Fadrozole hydrochloride hemihydrate	Inhibitor
Fadrozole hydrochloride hemihydrate is an orally active, potent, selective and nonsteroidal aromatase inhibitor, with an IC₅₀ of 6.4 nM. Fadrozole hydrochloride hemihydrate inhibits the production of estrogen and progesterone, with IC₅₀ values of 0.03 and 120 μM. Fadrozole hydrochloride hemihydrate shows prevention of spontaneous tumours. Fadrozole hydrochloride hemihydrate can be used for the research of estrogen-dependent disease and cancer.

HY-14274S

Anastrozole-d₁₂	Inhibitor
Anastrozole-d₁₂ is the deuterium labeled Anastrozole. Anastrozole is a potent, highly selective aromatase inhibitor, which inhibits human placental aromatase with an IC50 of 15 nM[1][2].

HY-18719ES

Endoxifen-d₅	Inhibitor
Endoxifen-d₅ is the deuterium labeled Endoxifen. Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study[1][2].

HY-146688

SYN20028567	Inhibitor
SYN20028567 is an aromatase (CYP19) inhibitor with an IC₅₀ of 9.4 nM. SYN20028567 can be used for breast cancer research.

Name
Email *

	Sorry, but the email address you supplied was invalid.